<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756180</url>
  </required_header>
  <id_info>
    <org_study_id>PUFA3001</org_study_id>
    <nct_id>NCT04756180</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.</brief_title>
  <official_title>A Placebo-Controlled, Multicenter, Randomized, Double-Blind, Parallel Group Study to Investigate the Efficacy and Safety of Omega-3-acid Ethyl Ester Over 12 Weeks in Chinese Subjects With Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to investigate the effect of 12-week treatment of Omacor on fasting&#xD;
      serum triglycerides (TG) in Chinese subjects with hypertriglyceridemia (HTG). The secondary&#xD;
      objectives were to investigate the safety and tolerability and effect of Omacor on lipid&#xD;
      parameters after 12 weeks treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, randomized, double-blind, parallel-group study of twice daily&#xD;
      treatment of Omacor or matching placebo in subjects with moderate or severe HTG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Double Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in fasting serum TG</measure>
    <time_frame>Baseline to end of treatment at treatment week 12</time_frame>
    <description>Percent change from baseline in fasting serum TG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol, LDL-cholesterol, HDL cholesterol, non-HDL-cholesterol and the LDL/HDL ratio</measure>
    <time_frame>Between baseline and end of treatment week 12</time_frame>
    <description>Change from baseline in total cholesterol, LDL-cholesterol, HDL cholesterol, non-HDL-cholesterol and the LDL/HDL ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Omacor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omacor 2gm/day for first 4 week followed by 4gms/day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Omacor Placebo 2gm/day for first 4 week followed by 4gms/day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3-acid ethyl ester or Placebo</intervention_name>
    <description>Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week</description>
    <arm_group_label>Omacor</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Baseline fasting serum TG level &gt; 200mg/dL and &lt;1000mg/dL, in subjects treated for&#xD;
             HTG.&#xD;
&#xD;
          -  If on previous statin therapy, the treatment should have been kept stable in the last&#xD;
             3 months before entering the study.&#xD;
&#xD;
          -  Able and willing to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects taking fish oil capsules 8 weeks prior to inclusion in this study.&#xD;
&#xD;
          -  Known allergy to the active ingredient, or fish, soya, corn or olive oild (placebos).&#xD;
&#xD;
          -  Pregnant of lactating females.&#xD;
&#xD;
          -  Known increased risk of hemorrhage such as recent surgery, gastrointestinal&#xD;
             hemorrhagic disease.&#xD;
&#xD;
          -  Significant hepatic disease.&#xD;
&#xD;
          -  Significantly reduced renal function.&#xD;
&#xD;
          -  Alcohol consumption &gt;30g for male and 20g for female daily.&#xD;
&#xD;
          -  Concomitant use of other investigational drugs.&#xD;
&#xD;
          -  Subject related to the investigator.&#xD;
&#xD;
          -  Subject expected to be not compliant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pooi Lee Chin</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

